Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

Abstract

Glutamate and gamma-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001021

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 124 references

Research works printed but not linked: 9

  1. Delgado PL . Depression: the case for a monoamine deficiency J Clin Psychiatry 2000 61 (Suppl 6): 7–11
  2. Cappiello A, Charney DS, Berman R et al. NMDA receptor function in major depression Biol Psychiatry 1997 41: 45S
  3. Mason GF, Haga K, Appel M et al. Measuring cortical GABA levels and neurotransmitter turnover with 1H-MRS and 13C-MRS Biol Psychiatry 2001 49: 148S
  4. Krystal JH, Petrakis IL, D'Souza DC, Trevisan L, Krasnicki S, Charney DS . Interactive effects of high dose intravenous glycine and oral D-cycloserine in healthy human subjects Biol Psychiatry 1997 41 (Suppl): 23S
  5. Blumberg HP, Leung HC, Wexler B et al. Ventral prefrontal dysfunction in bipolar disorder: an fMRI study Biol Psychiatry 2001 49: 26S
  6. Krystal JH, Belger A, Kirino E, Gore J, McCarthy G . Ketamine effects on the cortical processing of novelty in humans assessed with fMRI Soc Neurosci Abstr 1998 24: 104.7
  7. Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW . Guanabenz effects on NMDA antagonist-induced mental symptoms in human Soc Neurosci Abstr 1998 24: 211.2
  8. Lahti AC, Weiler MA, Parwani A et al. Blockade of ketamine-induced psychosis with olanzepine Schizophr Res 1999 36: 310
  9. Epperson CN, Mason G, Rothman DR, Sanacora G, Krystal JH . GABA dysregulation in premenstrual dysphoric disorder Soc Neurosci Abstr 1999 25: 2227

Cited by

See all 562

Metadata

Authors
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F.
Affiliations
Yale University (US)
Corresponding author
Krystal, J H
Venue
Molecular Psychiatry
Published
2002-01-01
Volume
7
Issue
S1
Pages
S71-S80
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2023866167
Cited by
553
References
124
Citations by year
2026: 8 · 2025: 14 · 2024: 14 · 2023: 17 · 2022: 17 · 2021: 49 · 2020: 21 · 2019: 16 · 2018: 20 · 2017: 17 · 2016: 29 · 2015: 19 · 2014: 25 · 2013: 31 · 2012: 28
FWCI
2.41
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (K23MH001830)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
glutamate, GABA, antidepressants, mood stabilizers, mood disorders, depression, mania, NMDA receptor, glutamatergic signaling, bipolar disorder, major depressive disorder, therapeutic target
MeSH terms
Antidepressive Agents, gamma-Aminobutyric Acid, Humans, Models, Neurological, Synaptic Transmission, Glutamic Acid, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. https://app.cochat.ai/papers/10.1038/sj.mp.4001021
The paper
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry. https://doi.org/10.1038/sj.mp.4001021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.